# DESCRIPTION

## FIELD OF THE INVENTION

- define field

## BACKGROUND OF THE INVENTION

- motivate HIV vaccine
- limitations of DNA platforms
- application of DNA-EP platform

## SUMMARY OF THE INVENTION

- define composition
- define first vaccine
- define second vaccine
- outline method of immunization

## DETAILED DESCRIPTION

- describe DNA vaccine encoding HIV antigenic constructs

### 1. DEFINITIONS

- define terminology
- explain singular forms
- explain numeric ranges
- define consensus sequence
- define peptide or polypeptide
- define treatment or treating
- define substantially identical
- define variant
- explain conservative substitution

### 2. COMPOSITION FOR PRIMING AND BOOSTING HIV IMMUNOLOGICAL RESPONSE

- introduce composition for priming and boosting HIV immunological response
- describe first vaccine composition
- specify nucleic acid sequences in first vaccine
- describe administration of first vaccine
- specify timing of first vaccine administration
- describe second vaccine composition
- specify antigenic peptides in second vaccine
- describe administration of second vaccine
- specify timing of second vaccine administration
- describe function of vaccine in inducing antigen-specific T cells
- describe enhancement of MHC Class II presentation and expression
- introduce antigen
- describe nucleic acid sequence encoding antigen
- specify HIV antigens
- describe genetic modifications of consensus sequences
- describe antigen of first vaccine across different HIV subtypes
- specify DNA sequences encoding particular protein sequences
- describe antigen of second vaccine
- specify consensus DNA sequences encoding particular protein sequences
- describe HIV antigen constructs
- introduce DNA
- describe DNA encoding antigen
- specify additional sequences in DNA
- introduce vector
- describe vector capable of expressing antigen
- specify expression signals in vector
- describe circular plasmid and linear nucleic acid vaccine
- specify promoter, intron, stop codon, and polyadenylation signal
- describe promoter and its function
- specify enhancer and intron
- describe transcription termination region
- introduce other components of vaccine
- describe pharmaceutically acceptable excipient
- specify transfection facilitating agents
- describe adjuvants
- specify genes encoding adjuvants
- describe other genes as adjuvants
- specify genetic vaccine facilitator agents
- describe formulation of vaccine

### 3. METHOD OF VACCINATION

- provide method of vaccinating patient
- administer composition to subject in need
- describe priming vaccination
- describe boost vaccination
- specify dose of first and second vaccine
- describe administration of first vaccine
- describe administration of second vaccine
- specify number of vaccine doses
- formulate composition for administration
- describe prophylactic administration
- describe therapeutic administration
- define therapeutically effective dose
- describe methods of administration
- cite references for administration methods
- describe delivery via particles or beads
- describe delivery via vaccine gun
- specify choice of pharmaceutically acceptable carrier
- describe parenteral administration
- describe oral administration
- describe intranasal administration
- describe intravaginal administration
- describe delivery to interstitial spaces
- describe delivery to muscle
- describe intradermal or subcutaneous injections
- describe transdermal administration
- describe epidermal administration
- describe nasal spray or drops administration
- describe aerosol administration by nebulizer
- describe liquid preparation administration
- describe liposome or microsphere administration
- describe electroporation administration
- describe minimally invasive device administration
- describe needle-free injector administration
- describe tissue penetration by jet of liquid
- describe electroporation by needle electrodes
- describe multiple electrode array administration
- describe single needle device administration
- describe pulse generator and injector administration
- describe modular electrode system administration
- describe Cellectra device and system administration
- describe Elgen 1000 system administration

### 4. EXAMPLES

- introduce example 1
- describe materials and methods
- detail animal housing and treatment
- outline cell and reagent preparation
- construct and express HIV-1 envelope consensus sequences
- immunize mice and guinea pigs
- analyze humoral immune response using ELISA
- analyze cellular immune response using ELISpot and flow cytometry
- perform T-cell ELISpot assay
- perform B-cell ELISpot assay
- analyze intracellular cytokine staining
- perform antibody binding assay using ELISA
- produce HIV-1 single round pseudovirus
- perform HIV-1 neutralization assay
- analyze statistical significance
- introduce example 2
- design HIV-1 envelope consensus DNA vaccines
- construct and express HIV-1 envelope plasmid
- verify expression using FACS analysis
- verify expression using indirect immuno fluorescence assay
- introduce example 3
- describe improved CD8 T-cell responses
- optimize HIV-1 envelope plasmid
- analyze CD8 T-cell responses
- discuss results of example 1
- discuss results of example 2
- discuss results of example 3
- summarize findings
- conclude examples
- introduce examples
- describe vaccine immunogenicity assessment
- motivate DNA prime-protein boost strategy
- describe ELISpot assay
- present results of DNA prime-protein boost
- describe antigen-specific T-cell responses
- present results of multi-clade DNA prime-protein boost
- describe polyfunctional T-cell responses
- present results of IFN-Î³ and IL-2 secretion
- describe gating strategy for intracellular cytokine flow cytometric analysis
- present results of multi-clade DNA prime and protein boost
- describe effects of multiple clade formulations and protein boost regimens
- present results of antibody binding titers
- describe B-cell ELISpot assay
- present results of B-cell responses
- describe correlation between antibody titer and B-cell ELIspot
- describe antibody levels in guinea pigs
- present results of binding ELISA
- describe Western blot analysis
- present results of neutralizing antibody response
- describe serum neutralization titer determination
- present results of NAbs activity
- describe discussion of results
- motivate improvements to DNA vaccination
- describe limitations of first-generation DNA vaccines
- describe improvements to DNA construct design and delivery methods
- describe effects of multi-clade DNA prime
- describe dosing study
- describe functional divergent T-cell response
- describe humoral response
- describe breadth of humoral response

## 5. CLAUSES

- define composition with first and second vaccines
- specify first vaccine with two nucleic acids
- specify first vaccine with three nucleic acids
- specify first vaccine with four nucleic acids
- specify antigens of first vaccine
- specify antigens of second vaccine
- specify antigenic peptide of first vaccine
- specify antigenic peptide of second vaccine
- specify first vaccine as priming vaccine
- specify second vaccine as boosting vaccine
- outline method of immunizing against HIV-1
- specify administration schedules for vaccines

